Lakefront Biotherapeutics NV (LKFT) Price Prediction & ForecastLKFTForecastLakefront Biotherapeutics NV

Alphio's LKFT stock price prediction model matches the current Lakefront Biotherapeutics NV tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $28.52 (-1.25%). The 1-week path is $27.38 (-5.18%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Lakefront Biotherapeutics appears to be a good buy right now due to its recent positive developments and favorable financial metrics. The current price is $28.88, which is below the analyst's revised price target of $26, indicating potential upside. The company has a strong gross margin of 99.95% reported in Q4 2025, and its recent FDA Orphan Drug Designation for Gamgertamig enhances its market potential. However, the main risk is the high forward P/E ratio of 344.83, indicating that the stock may be overvalued if growth does not materialize as expected.

Lakefront Biotherapeutics NV (LKFT) last closed at $28.88, losing -1.90%. These facts feed the 1-day and 1-week LKFT price prediction above.